Key PointsRevenue was flat at $16.6 billion, with COVID and Prevnar sales falling while Eliquis, Padcev, Vyndaqel, Nurtec, and Lorbrena grew.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.